review see ( 1 )]. As a consequence, components of this system, as well as pharmacological strategies to block endocannabinoid degradation, have been elucidated in past years [for review see ( 2 )].An integral component of the endocannabinoid system is the enzyme, fatty acid amide hydrolase (FAAH), a serine hydrolase fi rst identifi ed as the principal catabolic enzyme of the endocannabinoid, anandamide [ N -arachidonoylethanolamine (AEA)] ( 3 ). The second major endocannnabinoid, 2-arachidonoylglycerol (2-AG), can be hydrolyzed by multiple enzymes, including FAAH and monoacylglycerol lipase (MAGL), with about 85% of brain 2-AG hydrolase activity ascribed to MAGL ( 4 ). Likewise, FAAH is the catabolic enzyme for the endocannabinoid-like substances, Noleoylethanolamine (OEA) and N -palmitoylethanolamine (PEA) ( 5 ). In contrast to AEA and 2-AG, both endocannabinoid-like substances do not bind to the cannabinoid receptors, CB 1 and CB 2 , but share an activation of the nonselective cation channel transient receptor potential vanilloid 1 (TRPV1) ( 6-9 ) and the transcription factor PPAR ␣ ( 10-16 ) with endocannabinoids. In line with the latter notion, various biological effects of FAAH inhibitors have been associated with activation of PPAR ␣ ( 17-21 ).Several components of the endocannabinoid system, including CB 1 , CB 2 , TRPV1, and cannabinoid receptor ligands, have been reported as effectors of tissue healing